Hermetica Superfood Encyclopedia
The Short Answer
Sargassum muticum contains phenolic compounds, sulfated polysaccharides (fucoidan), and alginate that exert antioxidant activity through direct radical scavenging and cytoprotection of oxidatively stressed cells. Enriched fractions yield DPPH IC50 values as low as 32.29 µg/mL and reduce H2O2-induced MCF-7 cell viability loss by over 50%, while fucoidan fractions at 50–75 µg/mL stimulate fibroblast colony formation to 179% of control.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordSargassum muticum benefits
Sargassum muticum — botanical close-up
Health Benefits
**Antioxidant Protection**: Phenolic-rich EtOAc fractions containing up to 235
67 ± 1.13 µg GAE/mg exhibit potent DPPH and ABTS radical scavenging, with ORAC values reaching 3040.143 ± 266.235 µmol TE/g in vacuum-liquid-chromatography-enriched fractions.
**Cytoprotection Against Oxidative Injury**
Bioactive fractions (M-F7/F8 and MD-F1–4/F7) protect MCF-7 human breast epithelial cells from hydrogen peroxide-induced apoptosis, reducing viability loss by more than 50% at µg/mL concentrations without intrinsic cytotoxicity.
**Cardioprotective Potential**
Fucoidan and sulfated polysaccharides derived from S. muticum are associated with anticoagulant and cardioprotective effects consistent with broader Sargassum-class polysaccharide pharmacology, though direct cardiac endpoints in S. muticum remain preclinical.
**Wound Healing and Fibroblast Stimulation**
Fucoidan fractions at 50–75 µg/mL enhance L929 fibroblast colony formation to 179% of control values, suggesting applications in tissue repair and regenerative contexts.
**Anti-inflammatory Activity**
Polyphenolic constituents including vanillin and chrysin, alongside terpenoids and sargaquinoic acids, modulate inflammatory cascades, consistent with mechanisms documented across Sargassum genera in the 1974–2020 ethnopharmacological literature.
**Neuroprotective Properties**: Sulfated polysaccharides from S
muticum and related Sargassum species attenuate neurodegeneration-associated oxidative stress pathways in preclinical models, with broader class evidence implicating fucoidan in the suppression of neuroinflammatory signaling.
**Rich Nutritional Micronutrient Delivery**: S
muticum provides alginate at 17.40 ± 0.95% dry weight, the highest n-3 fatty acid content among tested Sargassum species, plus carotenoids, vitamins, and trace minerals relevant to baseline nutritional supplementation.
Origin & History
Natural habitat
Sargassum muticum is a brown macroalga native to the Pacific coasts of Japan, Korea, and China, and has since become an invasive species across the Atlantic coasts of Europe and the western coastlines of North America. It thrives in intertidal and subtidal zones, colonizing rocky substrates in temperate marine environments with high light availability. The alga grows rapidly under nutrient-rich coastal conditions and is harvested both from wild populations and, increasingly, from controlled aquaculture systems for bioactive compound extraction.
“Sargassum species, including S. muticum, have been integrated into the folk nutrition and traditional medicine of coastal East Asian communities—particularly in Japan, Korea, and China—for centuries, where they served as sources of iodine, vitamins, carotenoids, proteins, and dietary fiber well before their bioactive constituents were chemically characterized. In Japanese coastal communities, related Sargassum species were consumed as part of the traditional diet and used in poultices for analgesic and anti-inflammatory purposes, practices documented in ethnobotanical surveys spanning the twentieth century. S. muticum was first formally described in the scientific literature in the context of its westward invasion of European Atlantic coastlines in the 1970s, where it rapidly displaced native macroalgae and subsequently attracted scientific interest as a potential nutraceutical resource from an otherwise ecologically problematic invasive species. Contemporary interest in S. muticum reflects a broader trend of valorizing invasive marine biomass for pharmaceutical and food applications, with extraction studies expanding from the 1990s through the current decade.”Traditional Medicine
Scientific Research
Available evidence for Sargassum muticum is entirely preclinical, derived from in vitro assays and, to a limited extent, cell-viability models using MCF-7 and L929 cell lines without specified sample sizes or replicated independent cohorts. Antioxidant characterization studies using DPPH, ABTS, and ORAC assays across solvent-partitioned and vacuum-liquid-chromatography fractions provide reproducible phytochemical benchmarks, with the most potent fraction (MD-F8) achieving an IC50 of 32.29 µg/mL, but these do not translate directly to human pharmacokinetic efficacy. Fucoidan extraction optimization studies report fibroblast proliferative effects at 50–75 µg/mL in colony formation assays, representing the only cellular bioactivity endpoint with a quantified outcome beyond radical scavenging. No randomized controlled trials, observational studies, or pharmacokinetic investigations in human subjects have been published specifically for S. muticum, placing its evidence base firmly at the preclinical exploratory tier.
Preparation & Dosage
Traditional preparation
**Crude Hydroalcoholic Extract (MeOH or EtOH)**
No established human dose; in vitro active concentrations range from 32–75 µg/mL; traditional dietary incorporation as whole algae provides variable phytochemical loads.
**Ethyl Acetate (EtOAc) Partitioned Fraction**
Highest phenolic yield (up to 235.67 ± 1.13 µg GAE/mg); no standardized supplement dose established; research quantities used at µg/mL scale.
**Fucoidan Polysaccharide Extract**
Optimized aqueous or enzymatic extraction; fibroblast-stimulating activity observed at 50–75 µg/mL in vitro; no validated oral bioavailability or human dose range published.
**Alginate Fraction**
1–5 g/day in traditional seaweed-consuming populations
Comprises 17.40 ± 0.95% dry weight; used industrially as a food-grade gelling agent; typical dietary alginate intake from seaweed consumption is .
**Vacuum Liquid Chromatography (VLC) Enriched Fractions**
Laboratory-grade preparations (e.g., MD-F8) standardized by ORAC and DPPH; not commercially available as consumer supplements.
**Whole Dried Alga (Traditional Dietary Form)**
Consumed as part of coastal diets in East Asia and some European coastal communities; no quantified therapeutic dose specified in literature.
**Timing Note**
No pharmacokinetic data exist to guide dosing timing; general seaweed consumption is typically with meals to mitigate potential gastrointestinal effects from alginate gelling.
Nutritional Profile
Sargassum muticum provides total sugars at approximately 46.43 ± 0.12% dry weight, predominantly as structural and storage polysaccharides including alginate (17.40 ± 0.95% DW) and fucoidan. It contains the highest n-3 polyunsaturated fatty acid content among tested Sargassum species, though absolute concentrations have not been standardized across harvest seasons or geographic populations. Phenolic compounds reach up to 235.67 µg gallic acid equivalents per mg in enriched EtOAc extracts, with specific polyphenols identified including vanillin and chrysin. Micronutrients include iodine, calcium, magnesium, potassium, iron, and carotenoids (fucoxanthin class), alongside fat-soluble vitamins; bioavailability of these constituents from whole-alga consumption is influenced by alginate gelling, which may reduce mineral absorption through ionic binding, and by the cell wall polysaccharide matrix that limits extraction efficiency without processing.
How It Works
Mechanism of Action
The primary antioxidant mechanism of Sargassum muticum extracts involves direct hydrogen atom transfer and single-electron donation from phenolic hydroxyl groups to free radicals, as quantified in concentration-dependent DPPH inhibition assays across fractions spanning 2–32 mg/mL. Fucoidan, a sulfated fucose-rich polysaccharide, interacts with cell surface receptors and intracellular signaling mediators to suppress reactive oxygen species (ROS) generation, inhibit NF-κB-mediated inflammatory transcription, and modulate apoptotic cascades downstream of mitochondrial permeability transition pores. Polyphenols such as vanillin and chrysin contribute additional mechanisms via inhibition of pro-inflammatory cyclooxygenase and lipoxygenase enzymes, while sargaquinoic acids exhibit terpenoid-mediated membrane-stabilizing cytoprotection. Alginate-derived oligosaccharides further modulate gut microbiota composition and short-chain fatty acid profiles, creating systemic anti-inflammatory effects that extend beyond direct radical neutralization.
Clinical Evidence
No human clinical trials have been conducted on Sargassum muticum or its isolated fractions as of the current literature review. The entirety of outcome data originates from cell-free antioxidant assays and two cell-line models (MCF-7 epithelial cells and L929 fibroblasts), neither of which constitutes clinical evidence. Key quantified outcomes include greater than 50% preservation of MCF-7 viability under H2O2 stress and 179% fibroblast colony formation relative to untreated controls at fucoidan concentrations of 50–75 µg/mL. Confidence in human clinical benefit is currently low; extrapolation from in vitro data to therapeutic dosing, bioavailability, and efficacy in intact human physiology requires dedicated Phase I and Phase II trial programs.
Safety & Interactions
In vitro cytotoxicity screening of active fractions (M-F4, M-F6–F8, MD-F1–4, MD-F7) showed no significant cell death up to concentrations exceeding 1000 µg/mL in tested cell lines, suggesting a favorable preliminary safety window; however, no in vivo toxicology studies or human safety data for S. muticum extracts have been published. As a marine macroalga, S. muticum carries a class-level risk of heavy metal accumulation (including arsenic, lead, and cadmium) and elevated iodine content, both of which pose dose-dependent hazards in chronic or high-volume consumption—particularly for individuals with thyroid disorders, where excess iodine can precipitate hyperthyroidism or autoimmune thyroiditis. Fucoidan-class compounds from brown algae exhibit anticoagulant properties structurally analogous to heparin and may potentiate the effects of anticoagulant and antiplatelet medications such as warfarin, heparin, aspirin, and direct oral anticoagulants; concurrent use warrants clinical monitoring. No pregnancy or lactation safety data exist for S. muticum extracts; given the iodine load and anticoagulant polysaccharide content, conservative avoidance during pregnancy and lactation is advisable until human safety studies are available.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sargassum muticumWireweedJapanese wireweedSargassum fucansFucus muticus
Frequently Asked Questions
What is Sargassum muticum used for in health supplements?
Sargassum muticum is primarily investigated for its antioxidant, cytoprotective, and potential cardioprotective effects, driven by its content of sulfated polysaccharides (fucoidan), phenolic compounds, and alginate. Preclinical studies show its enriched fractions can reduce oxidative-stress-induced cell death in MCF-7 cells by over 50% and stimulate fibroblast proliferation to 179% of control at fucoidan concentrations of 50–75 µg/mL. No human supplement formulations with established dosing exist yet, as research remains at the in vitro stage.
What is fucoidan and how does it relate to Sargassum muticum?
Fucoidan is a sulfated fucose-rich polysaccharide found in the cell walls of brown macroalgae including Sargassum muticum, where it constitutes a significant portion of the bioactive polysaccharide fraction alongside alginate (quantified at 17.40 ± 0.95% dry weight for alginate). Fucoidan exerts anticoagulant, anti-inflammatory, and immunomodulatory effects by interacting with cell surface receptors and suppressing NF-κB-driven inflammatory gene expression. It is also the fraction most associated with fibroblast-stimulating and potential antiviral activity within S. muticum extracts.
Are there any human clinical trials on Sargassum muticum?
As of the current literature, no human clinical trials have been conducted on Sargassum muticum or any of its isolated fractions. All available efficacy data originate from cell-free radical scavenging assays (DPPH, ABTS, ORAC) and two cell-line models—MCF-7 human breast epithelial cells and L929 mouse fibroblasts—without validated translation to human pharmacokinetics or clinical outcomes. Substantial preclinical and early-phase clinical research would be required before therapeutic claims can be made with confidence.
Is Sargassum muticum safe to consume, and does it interact with medications?
In vitro cytotoxicity testing shows no harmful effects on cells at concentrations above 1000 µg/mL for most active fractions, suggesting a preliminary favorable safety profile. However, as a brown seaweed, S. muticum may contain elevated iodine and accumulated heavy metals (arsenic, lead) that pose risks with chronic use, and its fucoidan fraction carries anticoagulant properties that could enhance the blood-thinning effects of warfarin, heparin, and antiplatelet drugs. Individuals with thyroid disorders or those on anticoagulant therapy should exercise caution and consult a healthcare provider before using S. muticum-based products.
How does Sargassum muticum compare to other brown algae for antioxidant activity?
Sargassum muticum demonstrates competitive antioxidant potency relative to other Sargassum species, with its most enriched vacuum-liquid-chromatography fraction (MD-F8) achieving a DPPH IC50 of 32.29 µg/mL and an ORAC value of 3040.143 ± 266.235 µmol TE/g, alongside the highest n-3 fatty acid content among tested Sargassum species. Its phenolic content of up to 235.67 µg GAE/mg in EtOAc fractions is notably high within the genus, though direct head-to-head comparisons with commercially established brown algae such as Fucus vesiculosus or Ascophyllum nodosum under identical extraction conditions have not been published. Its antioxidant profile is shaped by extraction solvent polarity, with ethyl acetate fractions consistently outperforming methanol and butanol partitions.
What is the difference between Sargassum muticum extract and whole dried seaweed powder?
Sargassum muticum extract isolates and concentrates bioactive compounds like fucoidan and phenolics, achieving significantly higher antioxidant potency (ORAC values up to 3040 µmol TE/g in enriched fractions) compared to whole seaweed powder. Extracts provide standardized levels of active constituents, whereas whole powder contains variable amounts depending on harvest conditions and processing methods. Extracts are more suitable for targeted supplementation when specific bioactive concentrations are desired.
Which populations are most likely to benefit from Sargassum muticum supplementation?
Individuals seeking enhanced antioxidant protection and cellular defense against oxidative stress—particularly those with compromised cellular health or age-related oxidative concerns—may benefit from Sargassum muticum's cytoprotective compounds. The ingredient's ability to protect epithelial cells (demonstrated in MCF-7 cell models) suggests potential value for those interested in supporting cellular integrity in tissues frequently exposed to oxidative challenges. Persons already consuming limited brown algae in their diet may experience the greatest supplemental benefit.
How does the extraction method affect the potency of Sargassum muticum supplements?
Extraction method dramatically influences bioactive concentration; ethyl acetate (EtOAc) fractions achieve phenolic content up to 235.67 µg GAE/mg, while vacuum-liquid-chromatography enrichment further increases ORAC antioxidant values to 3040.143 µmol TE/g. Different solvents and chromatographic purification techniques selectively isolate distinct bioactive components, with enriched fractions demonstrating superior radical-scavenging capacity compared to standard extraction methods. This means supplement quality varies substantially based on manufacturer extraction protocols.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w sargassum-fucans-wireweed-sargassum-muticum curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
